Skip to main content
Boryung Corporation logo

Boryung Corporation — Investor Relations & Filings

Ticker · 003850 ISIN · KR7003850005 KO Manufacturing
Open in API
Filings indexed 354 across all filing types
Latest filing 2021-05-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 003850

About Boryung Corporation

https://pharm.boryung.co.kr/eng/index.do

Boryung Corporation is a fully integrated healthcare company founded in 1957. Its core business encompasses the research, development, manufacturing, and global commercialization of pharmaceutical products, with a significant presence in the cardiovascular therapeutic area. The company is distinguished by its pioneering 'Care in Space' (CIS) initiative, which focuses on developing healthcare solutions for humans in extreme environments and leveraging space for new research opportunities. In addition to its pharmaceutical operations, Boryung functions as a healthcare investment company, fostering innovation across the health sector. The company's diverse portfolio includes prescription drugs, over-the-counter products, and a pipeline aimed at addressing future medical needs.

Recent filings

Filing Released Lang Actions
분기보고서 (2021.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Boryung Pharmaceutical Co., Ltd. for the period of January 1, 2021, to March 31, 2021. It contains comprehensive financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2021
2021-05-14 Korean
[기재정정]증권신고서(지분증권) (2021.07)
Capital/Financing Update Classification · 95% confidence The document is a 'Correction Report' (정정신고) for a 'Securities Registration Statement' (증권신고서) filed by Boryung Pharmaceutical. It details specific amendments made to the original filing due to the submission of the company's 2021 Q1 report. The document contains detailed tables comparing 'Before Correction' and 'After Correction' data, including financial figures, R&D pipeline updates, and risk factors. Since this is a formal regulatory filing amending a previously submitted registration statement, it falls under the category of Regulatory Filings.
2021-05-14 Korean
투자설명서
Investor Presentation Classification · 95% confidence The document is a 'Securities Registration Statement' (증권신고서) for Boryung Pharmaceutical Co., Ltd., dated May 4, 2021. It details a capital increase (rights offering/public offering) of 5,550,000 shares. It includes sections on investment risks, business overview, and financial information typical of a prospectus or registration statement filed for capital raising purposes. In the provided taxonomy, this falls under 'Capital/Financing Update' (CAP) as it relates to fundraising and capital structure changes.
2021-05-04 Korean
[기재정정]증권신고서(지분증권) (2021.07)
Capital/Financing Update Classification · 95% confidence The document is a '정정신고(보고)' (Amendment Report) for a '증권신고서' (Securities Registration Statement) filed by Boryung Pharmaceutical. It details specific corrections to investment risks, use of proceeds, business status, and R&D expenses. In the context of financial filings, a Securities Registration Statement and its subsequent amendments are classified as Regulatory Filings (RNS) as they represent formal regulatory disclosures that do not fit into the other specific categories like 10-K, ER, or IP.
2021-04-30 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for Boryung Pharmaceutical for the first quarter of 2021. It provides key financial highlights such as revenue, operating profit, and net income in a summary table format. It is not a full report but an initial announcement of financial results, which fits the definition of an Earnings Release (ER). Q1 2021
2021-04-26 Korean
매매거래정지및정지해제(중요내용공시)
Share Issue/Capital Change Classification · 100% confidence The document is a short regulatory notice regarding the suspension and resumption of trading for Boryeong Pharmaceutical due to a bonus issue (capital change). It is a standard regulatory announcement issued to the exchange, fitting the criteria for a general regulatory filing as it does not represent the full report of the capital change itself, but rather the exchange-mandated trading notice.
2021-04-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.